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Background: The study is aimed to evaluate body composition and bone status in adolescent and adult patients
with active juvenile idiopathic arthritis (JIA) untreated with tumor necrosis factor alpha inhibitors.
Methods: Adult patients (12 male and 19 female) with active JIA and 84 healthy age- and gender- matched
controls were enrolled into the study. Body composition (tissue mass in grams, lean mass, fat mass and bone
mineral content as a fraction of tissue mass) and areal bone mineral density parameters (aBMD) at the lumbar spine,
proximal femur, femoral neck, distal radius and total body were assessed using dual energy x-ray absorptiometry
(DXA), and correlated with clinical characteristics of the disease and physical performance tests. Disease activity
was assessed using high-sensitivity C-reactive protein (hsCRP) and disease activity score 28 (DAS 28). Differences
between the groups were tested by t-test, and One-way ANOVA. Correlations were assessed using the Pearson
correlation coefficients and multiple linear regression analysis. Significances were counted at the 0.05 level.
Results: In patients with clinically active JIA (DAS 28, 6.36 ± 0.64, hsCRP, 18.36 ± 16.95 mg/l), aBMD at all
measured sites, bone mineral content (BMC) and lean mass were reduced, and fat mass was increased as
compared with healthy controls. Significant negative correlations were observed between BMC and disease
duration, use of glucocorticoids (GCs), and fat mass, respectively. A positive correlation was found between BMC
and lean mass, and between the body fat fraction and the use of GCs. Using multiple linear regression analysis,
lean mass was the only significant predictor of BMC of total body both in men and women, and of BMC of legs
(only in men). Lean mass was also the only predicting factor of total proximal femur BMD and femoral neck BMD.
No significant correlations have been determined among the body composition parameters and DAS 28 or
hsCRP endpoints.
Conclusions: In adult patients with long-term active JIA, lean mass was the main determining factor of total
body and leg BMC, and total proximal femur and femoral neck aBMD.
Keywords: JIA in adults, Disease activity, DAS 28, Body composition, Lean mass, Bone mineral density, Bone
mineral content, GlucocorticoidsBackground
Juvenile idiopathic arthritis (JIA) is a systemic connective
tissue disease with onset before age 16. This autoimmune
inflammatory disease is associated with potential focal and
systemic bone loss, and consequently with decreased bone
mineral density (BMD) [1,2], and a lifetime increased risk* Correspondence: maresova.kristyna@seznam.cz
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distribution, and reproduction in any mediumof fractures [3]. The pathophysiology of bone loss involves
especially deleterious effects of the pro-inflammatory cyto-
kines produced by the synovial membrane and also gluco-
corticoid (GC) treatment [4,5]. Both the excessive bone
resorption [5] and decreased bone formation and osteoblast
function are responsible for bone loss in patients with JIA
[6,7]. Reduced BMD is observed at all sites of the skeleton
in children, adolescents as well as in adults with JIA. In the
cross-sectional study, the low BMD in lumbar spine and
hip was found in 42–52% of adult patients with JIA [8].ioMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
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with JIA is well described [9]. In children and adolescents
with JIA, biological treatment with tumor necrosis factor
alpha (TNFα) blockers infliximab or etanercept is associ-
ated with a decrease in disease activity. A positive effect of
the therapy on the skeleton was also documented [10].
Decrease in bone mass in JIA is also associated with
muscle atrophy. A linear relationship was described be-
tween muscle cross-sectional area and bone mineral
content (BMC) of radial diaphysis in healthy children
and adolescents [11]. The bone-muscle unit plays an im-
portant role especially in the growing bones of children
and adolescents. It is the muscle forces, not body weight,
that load the load-bearing bones. Bones adapt their
strength to maintain the strain caused by physiological
loads close to a set point and the largest physiological
loads are caused by muscle contractions [12], and
muscle strength thus strongly influences postnatal
bone strength [13]. In JIA, inflammation, low physical
activity as well as the GC therapy may be responsible
for muscular atrophy.
Therefore, the aim of the present study is to assess the
association between disease activity, glucocorticoid ther-
apy, and body composition in adolescent and adult pa-
tients with long-term severe JIA before the initiation of
treatment with TNFα blockers. The results of this study
have showed significant differences between adult pa-
tients with active JIA and healthy controls in aBMD and
body composition. In JIA patients the lean mass was the
main determining factor of BMC of total body and legs,
and proximal femur and femoral neck aBMD.
Methods
Study design, participants
The study reports baseline data in 12 male and 19 female
adult patients with active JIA before the initiation of treat-
ment with TNFα blockers. According to the criteria of
the Czech Rheumatology Society, the basic indication for
therapy with TNFα inhibitors is an unsatisfactory re-
sponse to therapy with one disease-modifying anti-
rheumatic drug (DMARD) (preferably methotrexate,
alternatively sulphasalazine or leflunomide). DMARD
therapy before TNFα blockers initiation must be at
least 3-6 months with adequate dosage (methotrexate
dose 20-30 mg). The other basic condition is a disease
activity score 28 (DAS 28) of at least ≥ 3.9 [14]. The
lowest DAS 28 in our JIA group was 5.1.
The control sample of young men and women with no
fracture was recruited by invitation in the same district
of Prague. The volunteer group (100 subjects) was se-
lected randomly from classmates, friends and acquain-
tances of JIA patients. From these invitations, three
eligible age- and gender- matched control participants
(only 2 control participants in 9 females) were selectedfor each JIA case. Wherever a precise match by the year
of birth was not possible, the closest matching case was
selected in most cases up to a maximum of a 2-year age
difference (rarely up to a maximum of 6-year age differ-
ence). Thus, 84 controls were available from the volunteer
group, and the age of the volunteers was matched for the
age of patients.
The patients and controls were examined in the Insti-
tute of Rheumatology in Prague. All participants gave
their written informed consent before enrollment. The
study protocol and informed consent documents were
prepared in compliance with the Declaration of Helsinki
and approved by the local ethical review board. The
study was approved by the Ethics Committee of the
Institute of Rheumatology. The authors have complied
with the World Medical Association Declaration of
Helsinki regarding ethical conduct of research involv-
ing human subjects.
The subjects completed clinical examination, bone min-
eral density and body composition measurement and blood
sampling. The type and duration of disease and previous
therapy were recorded for each patient. A complete clinical
history, including details of co-morbidity, detailed personal
history of JIA, GC use (previous or ongoing, dosage, dur-
ation, and route of administration), fracture history (type
and trauma), alcohol intake, smoking, height loss, family
history of osteoporosis and hip fracture, and physical exam-
ination were assessed by the same physician. The control
subjects were not supplemented with vitamin D and cal-
cium. The JIA patients were supplemented with 1000 mg
calcium and 800 IU vitamin D daily, for at least six months
prior to evaluation. The body height was measured with a
stadiometer and body weight with an accurate scale.
Disease activity
Disease activity was assessed using high-sensitivity
C-reactive protein (hsCRP) and DAS 28. hsCRP serum
concentrations were measured using immunoturbidi-
metry. Inter-day coefficient for variation for hsCRP
was 1.9%. DAS 28 was assessed using DAS 28 calcula-
tor including objective clinical, laboratory as well
as subjective components. The components were the
number of tender and swollen joints (from the total
number of 28), erythrocyte sedimentation rate and pa-
tient global health (0 = best, 100 = worst).
Bone densitometry
Dual energy x-ray absorptiometry (DXA, bone densi-
tometer Prodigy, GE, U.S.A., Software 12.10.113) was
used to measure aBMD at lumbar spine, total proximal
femur, femoral neck, femur trochanter and distal radius.
The short-term in-vivo precision errors for lumbar
spine, total femur, femoral neck and distal radius BMD
were 0.7%, 0.9%, 1.8% and 0.9%, respectively; the long-






No of participants 31 84
Male/female (No) 12/19 36/48 0.692
Age (years) 25.1 ± 6.1 23.8 ± 4.5 0.405
Anthropometric measures
Age (years) 25.1 ± 6.1 23.8 ± 4.5 0.405
Height (cm) 170.5 ± 9.8 173.3 ± 9.3 0.145
Weight (kg) 68.0 ± 12.5 69.2 ± 12.5 0.884
BMI (kg/m2) 23.4 ± 3.9 22.9 ± 3.0 0.435
Clinical data







Smoking (No) 7 13 0.372
Alcohol abuse (No) 0 0
Menarche (years) 13.1 ± 1.2 12.9 ± 1.1 0.994
Contraception in female (No) 11 23 0.462
Serum 25(OH)D (nmol/l) 65.9 ± 42.6 50 ± 28.5 0.029
Disease activity
DAS 28 6.36 ± 0.64 -
hsCRP (mg/l) 18.36 ± 16.95 1.40 ± 1.63 <0.001
Displayed are numbers or means ± SD. Clinical characteristics with zero value
were not statistically calculated.
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0.31%. Daily scanning of a phantom showed an absence
of machine drift during the study. aBMD was expressed
in g/cm2 and in T-scores. Normative values provided by
GE Prodigy were used for the determination of T-scores
(comparison with an average bone density of young
healthy adults of the same gender). In all subjects, the
DXA was measured using the same instrument and
technician in order to eliminate operator discrepancies,
and it was assessed by the same physician.
The availability of DXA enables the precise measure-
ment of body composition in terms of lean and fat mass
and bone mineral content of the total body, trunk, legs
and arms. In our study we calculated percentages for
lean mass, fat mass and BMC evaluation. BMC, lean
mass and fat mass were measured using whole-body
absorptiometry software of the bone densitometer (Prod-
igy, GE, U.S.A.) and were expressed in grams. Percentages
of BMC, lean mass and fat mass were calculated by divid-
ing each absolute value by total mass. For instance per-
centage trunk fat was calculated by dividing trunk fat
mass by total fat mass and was designated (%) trunk fat. A
strong correlation between body weight and total body
mass as measured by DXA (r = 0.98) was obtained in a
preliminary study. The coefficients of variation of mea-
surements of BMC, lean and fat mass were 0.9, 1.0 and
2.0%, respectively.
Physical performance tests of lower limbs (legs)
The authors used 2 tests for muscle strength of lower
limbs assessment. In chair rise test the goal was to get
up from a chair and then to sit down as quickly as pos-
sible 5 times in a row (seconds); the lower the value, the
better the result of lower extremity muscle strength.
Walking speed was calculated based on the time needed
to complete the required number of meters (meters per
second); the higher the value, the better the result of
lower extremity muscle strength.
Statistical methods
Thirty one JIA patients and 84 age- and gender-matched
control individuals were included in the analysis. Sum-
mary statistics including group size, mean, and SD were
reported for each parameter. Differences between the
groups were tested by t-test, and One-way ANOVA.
Correlations were assessed using the Pearson correlation
coefficients and multiple linear regression analysis. Sig-
nificances were counted at the 0.05 level.
Results
Summary statistics of the JIA patients and healthy con-
trol subjects are given in Table 1. The mean of JIA onset
was at the age of 10.3 ± 4.9 years and disease duration
was 14.6 ± 9.1 years. The JIA subtypes seen in patientswere as follows: polyarticular in 16 patients (rheumatoid
factor positive in 4, rheumatoid factor negative in 12),
enthesitis-related arthritis in 9 patients, extended oli-
goarticular in 4 patients, psoriatic in 2 patients. Func-
tional class I was determined in 18 patients, II in 4, III
in 5, and IV in 4 patients. 6 patients were ANA positive.
Cervical spine involvement was found in 7 patients. No pa-
tients suffered from vasculitis or lung impairment. In
females, the menarche age was 13.1 ± 1.2 years. In JIA pa-
tients the value of Health Assessment Questionnaire was
0.97 ± 0.60 and EuroQol Questionnaire was 0.56 ± 0.27.
At the time of study recruitment, all of the patients
were treated with DMARDs, 23 with methotrexate
(mean dose of 16.8 ± 3.4 mg/week), 4 with leflunomide, 2
with sulphasalazine, 1 with sulphasalazine + hydroxychloro-
quine sulfate and 1 with cyclosporine A. Nine women and
3 men were current users of GCs, 10 patients with Prednis-
one, 2 patients with Medrol. In these patients the average
dose of GCs was 6.7 ± 4.3 mg/day, median dose 5 mg/day,
range 4-20 mg/day. 14 patients were past users of GCs and
5 patients had never used GCs.
No prevalent clinical vertebral fractures were demon-
strated in the subjects under study. In the JIA patients,
morphometric vertebral fractures were documented in 5
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fractures were observed in the control subjects. No par-
ental history of hip fracture was reported in subjects
under study. Smoking was reported in 7 patients and al-
cohol abuse was not reported. No statistical differences
of demographic characteristics between the patientTable 2 BMD, body composition, and physical performance






LS BMD (g/cm2) 1.09 ± 0.15 1.226 ± 0.10 <0.001
LS T-score -0.54 ± 1.09 0.25 ± 0.85 0.003
Total femur
BMD (g/cm2)
0.92 ± 0.16 1.14 ± 0.10 <0.001
Total femur T-score -0.94 ± 1.13 0.67 ± 0.77 <0.001
Femoral neck
BMD (g/cm2)
0.93 ± 0.17 1.13 ± 0.11 <0.001
Femoral neck T-score -0.97 ± 1.21 0.54 ± 0.88 <0.001
Trochanter BMD
(g/cm2)
0.69 ± 0.14 0.89 ± 0.10 <0.001
Trochanter T-score -1.73 ± 1.35 -0.01 ± 0.97 <0.001
Distal radius BMD (g/cm2) 0.68 ± 0.08 0.73 ± 0.07 0.007
Distal radius T-score -0.59 ± 1.06 -0.30 ± 0.77 0.168
Total body BMD (g/cm2) 1.07 ± 0.19 1.21 ± 0.08 <0.001
Total body T-score -0.40 ± 0.92 0.64 ± 0.82 <0.001
Total body composition
Tissue mass (g) 63914 ± 11660 66813 ± 12338 0.273
Fat mass (%) 31.67 ± 10.63 24.93 ± 8.71 0.001
Lean mass (%) 64.64 ± 10.28 70.86 ± 8.52 0.002
BMC (%) 3.70 ± 0.48 4.20 ± 0.40 <0.001
Arms composition
Tissue mass (g) 7116 ± 1846 7446 ± 2017 0.578
Fat mass (%) 30.28 ± 12.23 21.79 ± 11.03 <0.001
Lean mass (%) 65.47 ± 11.69 73.28 ± 10.71 0.001
BMC (%) 4.25 ± 0.80 4.94 ± 0.69 <0.001
Legs composition
Tissue mass (g) 22922 ± 4009 23974 ± 4134 0.238
Fat mass (%) 34.86 ± 12.03 26.62 ± 9.36 <0.001
Lean mass (%) 61.33 ± 11.54 68.89 ± 9.04 <0.001
BMC (%) 3.82 ± 0.62 4.49 ± 0.50 <0.001
Trunk composition
Tissue mass (g) 30207 ± 6538 31302.0 ± 6245 0.426
Fat mass (%) 31.20 ± 11.28 25.84 ± 9.15 0.013
Lean mass (%) 66.39 ± 11.10 71.31 ± 9.03 0.021
BMC (%) 2.41 ± 0.37 2.85 ± 0.32 <0.001
Chair rise (5x) (sec) 10.29 ± 4.07 6.24 ± 1.47 <0.001
Walking rate (m/sec) 1.22 ± 0.33 1.40 ± 0.27 0.002and control group were found except for higher serum
25-hydroxyvitamin D levels in the JIA patients.
Compared to healthy controls, aBMD in JIA patients
was lower at all measured sites (Table 2). In the total
body as well as in the trunk and extremities (both legs
and arms), no significant differences in tissue mass were
observed between JIA patients and control subjects.
However, in all measured regions, lean mass and BMC
fraction was significantly lower, and fat mass fraction
was significantly higher in JIA patients compared to
controls. Chair rise test and walking speed in patients
with JIA was significantly worse as compared with the
control subjects (Table 2). Significant differences in
body composition between JIA and controls were also
evident in both genders (Table 3). BMC was reduced in
all the measured sites, lean mass was reduced as well
and fat mass was increased in all measured areas ex-
cept for the trunk.Table 3 Body composition in women and men with JIA
Women JIA (n =19) Controls (n = 48)
Region Mean ± SD Mean ± SD p
Total body Fat (%) 36.73 ± 8.72 29.92 ± 7.48 0.003
Lean (%) 59.68 ± 8.37 65.88 ± 7.14 0.005
BMC (%) 3.59 ± 0.45 4.20 ± 0.47 <0.001
Arms Fat (%) 37.27 ± 9.46 28.64 ± 9.76 0.003
Lean (%) 58.65 ± 8.77 66.39 ± 9.08 0.004
BMC (%) 4.08 ± 0.92 4.97 ± 0.82 <0.001
Legs Fat (%) 41.63 ± 9.11 32.96 ± 6.96 <0.001
Lean (%) 54.81 ± 8.78 62.73 ± 6.64 <0.001
BMC (%) 3.56 ± 0.53 4.30 ± 0.54 <0.001
Trunk Fat (%) 34.98 ± 10.81 29.84 ± 8.68 0.057
Lean (%) 62.71 ± 10.73 67.31 ± 8.51 0.084
BMC (%) 2.31 ± 0.32 2.85 ± 0.37 <0.001
Men JIA (n = 12) Controls (n = 36)
Region Mean ± SD Mean ± SD p
Total body Fat (%) 24.07 ± 8.69 18.59 ± 5.46 0.015
Lean (%) 72.07 ± 8.34 77.21 ± 5.32 0.019
BMC (%) 3.86 ± 0.48 4.20 ± 0.29 0.006
Arms Fat (%) 19.79 ± 7.48 13.27 ± 4.87 0.001
Lean (%) 75.69 ± 7.16 81.83 ± 4.72 0.002
BMC (%) 4.52 ± 0.50 4.90 ± 0.50 0.031
Legs Fat (%) 25.56 ± 8.99 18.74 ± 4.86 0.002
Lean (%) 70.25 ± 8.55 76.55 ± 4.71 0.003
BMC (%) 4.20 ± 0.54 4.71 ± 0.35 <0.001
Trunk Fat (%) 25.53 ± 9.81 20.87 ± 7.11 0.087
Lean (%) 71.90 ± 9.58 76.27 ± 7.03 0.102
BMC (%) 2.56 ± 0.41 2.86 ± 0.25 0.006
Figure 1 Body composition of total body and legs in women with JIA not treated with GCs (gray bars), in women with JIA treated with
GCs (black bars) and in women from the control group (empty bars). *p < 0.05, One-way ANOVA.
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body and legs was significantly different from that in
women untreated with glucocorticoids and from that in
women in the control group (Figure 1).
In JIA patients, significant correlations were observed
between indices of composition of legs, and physical per-
formance and disease duration (Table 4). Significant cor-
relations were also observed in these patients between
the indices of body composition by gender (Table 5).
Thanks to the inclusion of a number of female patients
treated with GCs, it was possible to observe a significant
negative correlation between GCs usage and BMC of
legs, and between GCs usage and DAS 28. The associ-
ation between lean mass and BMC in legs of women
with JIA treated with GCs, not treated with GCs, and
healthy women as well as in men with JIA and control
subjects is given in Figure 2.
Using multiple linear regression analysis, the fraction
of BMC was significantly predicted by total body lean
mass both in women (total body, p = 0.002) and in men
(total body, p = 0.022, and in legs, p = 0.008), while
current GC therapy, DAS28, and duration of disease did
not contribute significantly to the prediction of the BMC
in the patients with JIA.Table 4 Pearson correlation coefficients between body compo
in patients with JIA
Glucocorticoids Disease duration






*p < 0.05; **p < 0.01.Discussion and conclusions
In our study of TNFα blocker naïve patients with JIA, a
reduction of aBMD at all measured areas of the skeleton,
except the distal radius T-score was observed. Decreased
aBMD has been reported also in children and adoles-
cents with JIA at all skeletal sites. Zak et al. described
low bone mass density in LS spine and hips in 42-52%
of adult JIA patients, both male and female [8]. In our
study, a statistically significant dependence was seen be-
tween bone mass density parameters (BMD in g/cm2
and T-score in the area of proximal femur, femoral neck
and trochanter, BMD in g/cm2 of distal radius and total
body T-score) and the lean mass. Significant correlations
were observed between BMC and disease duration, GCs
usage and lean mass, respectively. Lean mass was the
only determining factor of total proximal femur BMD
and femoral neck BMD. Also, lean mass was the main
determinant of the total body BMC both in women and
men, and also of the leg BMC in men. This is in good
agreement with the observations on body composition
in non-corticosteroid–treated postpubertal women and
in prepubertal children with JIA [15-17].
The differences between body composition of total
body and legs in the subgroup of women with JIAsition of legs, physical performance and disease duration
Fat tissue (%) Lean tissue (%) BMC (%) DAS28
0,40* -0,40* -0,23 0,13
0,43* -0,43* -0,43* 0,50**




Table 5 Pearson correlation coefficients between composition of legs in women and men with JIA
Women Disease duration Fat tissue (%) Lean tissue (%) BMC(%) DAS28
Glucocorticoids 0,29 0,46 -0,44 -0,50* 0,53*
Disease duration (yrs) 0,46 -0,45 -0,48* -0,27
Fat tissue (%) -1.00*** -0,64*** 0,05
Lean tissue (%) 0,61** -0,04
BMC (%) -0,13
Men Disease duration Fat tissue (%) Lean tissue (%) BMC (%) DAS28
Glucocorticoids -0,16 0,33 -0,34 -0,23 0,32
Disease duration (years) 0,31 -0,31 -0,27 -0,02
Fat tissue (%) -1.00*** -0,83*** -0,04
Lean tissue (%) 0,81** 0,04
BMC (%) -0,10
*p < 0.05; **p < 0.01; ***p < 0.001.
Figure 2 Correlations between lean tissue and BMC fractions in
legs in women (upper panel) and in men (lower panel); control
subjects (empty circles, full line, women, r = 0.58, p < 0.001,
men, r = 0.43, p = 0.017), women with JIA not treated with
glucocorticoids (full triangles, dashed line, r = 0.47, p = 0.17),
women with JIA treated with glucocorticoids (full squares,
dotted line, r = 0.43, p = 0.29) and men with JIA (full circles,
dashed line, r = 0.81, p = 0.001).
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fect of GCs on the lean mass and BMC, and the positive
effect on fat tissue. This is in good agreement with sev-
eral cross-sectional and longitudinal studies demonstrat-
ing substantial effects of GCs on muscle atrophy and
body composition in patients with medical illnesses such
as Crohn’s disease, multiple sclerosis, systemic lupus ery-
thematosus, glucocorticoid-sensitive nephrotic syndrome
and post-renal transplantation [18-23]. The significant
positive correlation between the activity of the disease
and GC use could be explained by the necessity of GC
therapy in patients with severe course of disease. How-
ever, while 9 out of 19 women patients were on GC ther-
apy, the BMC fraction was significantly predicted by GC
use rather than by DAS28. The importance of lean mass
is further supported by the significant correlation be-
tween disease duration and increase of fat mass and re-
duction of bone and lean mass and deteriorated
physical performance of legs evaluated using the chair
test. In a study where lean mass and cortical and
trabecular bone forearm BMD were measured using
peripheral quantitative computed tomography, JIA pa-
tients had significantly reduced muscle cross-sectional
area and this reduction significantly correlated with
muscle strength and bone geometry abnormalities and,
particularly, with reduced thickness of the cortical
bone [24]. Similar conclusions were derived from the
measurement of muscle and bone mass of the tibia
[25]. Prolonged exposure to GCs can lead to muscle
atrophy.
The aforementioned results support the hypothesis
that muscles (at least in adults) play a dominant role in
the synchronization of muscle and bone mass [26]. This
closely linked function and form of both tissues may be,
from the embryonic development to the old age, influenced
by genetic dispositions, morphogenic factors, sex steroids
Brabnikova Maresova et al. BMC Musculoskeletal Disorders 2014, 15:51 Page 7 of 8
http://www.biomedcentral.com/1471-2474/15/51and, in adulthood, particularly mechanical signals [27], inter
alia through myokines (myostatin, leukemia inhibitory fac-
tor, interleukin 6, interleukin 7, insulin-like growth factor 1,
fibroblast growth factor 2, follistatin-like protein and irisin)
[28]. The myostatin/activin signaling pathway may be
involved in both muscle and bone coordination [29].
Increased cytokine production during long-lasting inflam-
mations induces protein degradation, inhibits myocyte
differentiation and induces apoptosis of myocytes and my-
opathy [30]. In JIA, inflammation may be, through muscu-
lar mass reduction, responsible also for reduced bone mass.
As muscles are the main source of myostatin and the
administration of glucocorticoids is associated with an in-
creased production of myostatin, muscular atrophy and
increased secretion of myostatin in active JIA further sup-
presses new bone formation and induces reduction of
BMD [31,32]. The cause of the myopathic condition is not
necessarily limited to the inflammatory cytokines – it could
also involve GCs and the lower physical activity in JIA pa-
tients [24,30]. Glucocorticoids not only decrease muscle
anabolism by inhibiting amino acid transport into the
muscle [8], but also increase muscle catabolism [33]. GCs
play a key role in inducing proteolysis in acute inflamma-
tory states via the autophagy and the ubiquitin–proteasome
pathways [34].
Several limitations of the study must be taken into ac-
count. First, the sample size was not large enough to
make definite conclusions by multiple logistic regression
analysis. Secondly, the results do not allow for an assess-
ment of the association of changes in tissue composition
with the risk of fracture [35]. The established correla-
tions between mass and bone unit may be influenced by
genetic factors [36] and individual differences in physical
activity and diet [37,38] that were not controlled in this
study. Also, individual patient susceptibility to adverse
effects of GCs depends on GC dose, duration of therapy,
GC receptor saturation levels and GC receptor gene
polymorphisms [33]. The cross-sectional nature of the
study does not allow for a more accurate assessment of
the muscular-bone unit relationship in individual pa-
tients and the disease activity.
The results of this study show significant effects of both
the disease and GC therapy on aBMD and body compos-
ition in patients with JIA and support the hypothesis of the
dominant role of muscles in the synchronization of muscu-
lar and bone mass.
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